Monday, October 3, 2022


Biotechnology News Magazine

Sciwind Biosciences Secures US$37 Million Series B Financing

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 19, 2021

Hangzhou Sciwind Biosciences Co., Ltd. is a fast growing biopharmaceutical company focusing on research and development of innovative biologics.  They announced the closing of a US $37 Million Series B financing.

The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.

Sciwind Biosciences focuses on the research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials. A phase 1 clinical study of XW003, has been completed in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity, and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021. Two more Investigational New Drug (IND) applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analog.

”Sciwind is now entering an exciting new era. We welcome the new investors and greatly appreciate the strong support of existing investors. The successful completion of series B financing shows the confidence of the investors in Sciwind team and R&D projects,” said Hai Pan, Ph.D., Sciwind’s founder, and CEO. “The new investment will help to drive current clinical projects and push forward other First-in-Class/Best-in-Class drug candidates from our pipeline into clinical development. It also helps the expansion of our talented team and we hope to -attract more talents to join Sciwind team to provide patients with products of high clinical value and bring a sustained financial return to the investors.”

Mr. Gang Chen, Partner at LYFE Capital, said “We are very pleased to be an investor and partner of Sciwind. LYFE Capital is committed to investing in biopharmaceutical companies with extraordinary management teams and great prospects. Sciwind stands out due to its strong R&D capability and highly experienced management team, which makes us very confident about the future of Sciwind. In addition to financial support, we will make every effort to provide Sciwind with more support, such as global partnerships, collaborations, regulatory guidance, and local market access.”

Mr. Tan Hong, Managing Director at Legend Capital, said “Sciwind is one of the elite biopharmaceutical companies in China and its innovative and entrepreneurial culture has always impressed us. Since our last investment in Sciwind in 2019, we are delighted to see a series of progress achieved by Sciwind. We look forward to working closely with the talented team at Sciwind and other investors to improve patients’ quality of life”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine